Considering as cut-off the median value of melanoma cells expressing IFNAR1 (range: 20–90, Wilcoxon test), patients with a pre-treatment percentage of melanoma cells positive for IFNAR1 of ≤ 35% had a median PFS of 12.0 months (range: 5.6–18.4 months), while patients with a percentage of melanoma cells expressing IFNAR1 of > 35% had a median PFS of 4.0 months (range: 0–8.8 months) (p = 0.03) (Fig. 5a). This evidence concerns the gene IFNAR1 and melanoma.